{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:12:41Z","timestamp":1772856761165,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Journal Armed Forces India"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.mjafi.2025.03.003","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T07:18:07Z","timestamp":1745997487000},"page":"6-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring the therapeutic potential of beta-3 adrenergic agonists in overactive bladder: A comprehensive review"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9372-2680","authenticated-orcid":false,"given":"Veena","family":"Nayak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2600-4435","authenticated-orcid":false,"given":"Sadhana N.","family":"Holla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-1855","authenticated-orcid":false,"given":"Smita","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1654-6342","authenticated-orcid":false,"given":"Harshini","family":"H","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya Vinayak","family":"Raveendran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.mjafi.2025.03.003_bib1","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4140\/TCP.n.2014.823","article-title":"Mirabegron: a beta-3 agonist for overactive bladder","volume":"29","author":"Rebecca","year":"2014","journal-title":"Consult Pharm"},{"issue":"3","key":"10.1016\/j.mjafi.2025.03.003_bib2","article-title":"Prevalence of and associated factors for overactive bladder subtypes in middle-aged women: a cross-sectional study","volume":"58","author":"Yang","year":"2022","journal-title":"Medicina (Lithuania)"},{"key":"10.1016\/j.mjafi.2025.03.003_bib3","series-title":"StatPearls","article-title":"Anatomy, abdomen and pelvis: bladder detrusor muscle","author":"Sam","year":"2023"},{"issue":"1","key":"10.1016\/j.mjafi.2025.03.003_bib4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/j.2040-4603.2015.tb00596.x","article-title":"Neural control of the lower urinary tract","volume":"5","author":"de Groat","year":"2015","journal-title":"Compr Physiol"},{"issue":"1","key":"10.1016\/j.mjafi.2025.03.003_bib5","article-title":"An overview of the clinical use of antimuscarinics in the treatment of overactive bladder","volume":"2011","author":"Athanasopoulos","year":"2011","journal-title":"Adv Urol"},{"issue":"6","key":"10.1016\/j.mjafi.2025.03.003_bib6","first-page":"345","article-title":"Management of urinary incontinence","volume":"37","author":"Demaagd","year":"2012","journal-title":"P T"},{"issue":"4","key":"10.1016\/j.mjafi.2025.03.003_bib7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1517\/17460441.2014.892923","article-title":"Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence","volume":"9","author":"Sacco","year":"2014","journal-title":"Expet Opin Drug Discov"},{"issue":"1","key":"10.1016\/j.mjafi.2025.03.003_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1573402114666180918102735","article-title":"Three generations of \u03b2-blockers: history, class differences and clinical applicability","volume":"15","author":"do Vale","year":"2018","journal-title":"Curr Hypertens Rev"},{"issue":"2","key":"10.1016\/j.mjafi.2025.03.003_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/biom14020159","article-title":"Inside the biology of the \u03b23-adrenoceptor","volume":"14","author":"Pasha","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.mjafi.2025.03.003_bib10","article-title":"Inhibition of prejunctional parasympathetic pathways by \u03b23-adrenoceptor agonists in the isolated pig detrusor: comparison with human detrusor studies","volume":"14","author":"D'Agostino","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.mjafi.2025.03.003_bib11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1152\/physrev.00030.2012","article-title":"Urothelial signaling","volume":"93","author":"Birder","year":"2013","journal-title":"Physiol Rev"},{"issue":"14","key":"10.1016\/j.mjafi.2025.03.003_bib12","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1111\/bph.14658","article-title":"\u03b23 -Adrenoceptors in the normal and diseased urinary bladder- what are the open questions?","volume":"176","author":"Igawa","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.mjafi.2025.03.003_bib13","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.juro.2009.12.060","article-title":"Bladder afferent signaling: recent findings","volume":"183","author":"Kanai","year":"2010","journal-title":"J Urol"},{"issue":"suppl 3","key":"10.1016\/j.mjafi.2025.03.003_bib14","first-page":"s113","article-title":"New targets for overactive bladder-ICI-RS 2109","volume":"39","author":"Fry","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.mjafi.2025.03.003_bib15","article-title":"Concentration-dependent alpha1-adrenoceptor antagonism and inhibition of neurogenic smooth muscle contraction by mirabegron in the human prostate","volume":"12","author":"Huang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.mjafi.2025.03.003_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13318-016-0350-5","article-title":"Pharmacokinetic interactions between mirabegron and metformin, warfarin, digoxin or combined oral contraceptives","volume":"42","author":"Groen-Wijnberg","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"21","key":"10.1016\/j.mjafi.2025.03.003_bib17","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1111\/bph.14121","article-title":"Mirabegron: potential off target effects and uses beyond the bladder","volume":"175","author":"Dehvari","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.mjafi.2025.03.003_bib18","article-title":"Impact of mirabegron administration on the blood pressure and pulse rate in patients with overactive bladder","volume":"58","author":"Ito","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.mjafi.2025.03.003_bib19","series-title":"Natural Medicine","first-page":"1533","article-title":"Lower urinary tract symptoms, overactive bladder syndrome, and urinary incontinence (LUTS, OAB, and UI)","author":"Seipel","year":"2020"},{"issue":"5","key":"10.1016\/j.mjafi.2025.03.003_bib20","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/JU.0000000000001574","article-title":"Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR)","volume":"205","author":"Staskin","year":"2021","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.mjafi.2025.03.003_bib21","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cpdd.1169","article-title":"Pharmacokinetics and safety of vibegron 75 mg administered as an intact or crushed tablet in healthy adults","volume":"11","author":"King","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"10.1016\/j.mjafi.2025.03.003_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14656566.2020.1809652","article-title":"Evaluating vibegron for the treatment of overactive bladder","volume":"22","author":"Rechberger","year":"2021","journal-title":"Expet Opin Pharmacother"},{"issue":"5\u20136","key":"10.1016\/j.mjafi.2025.03.003_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1540\/jsmr.48.115","article-title":"Effects of ritobegron (KUC-7483), a novel \u03b23-adrenoceptor agonist, on both rat bladder function following partial bladder outlet obstruction and on rat salivary secretion: a comparison with the effects of tolterodine","volume":"48","author":"Maruyama","year":"2012","journal-title":"J Smooth Muscle Res"},{"issue":"1","key":"10.1016\/j.mjafi.2025.03.003_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.euf.2018.04.005","article-title":"Lower urinary tract symptoms: what's new in medical treatment?","volume":"4","author":"Peyronnet","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.mjafi.2025.03.003_bib25","first-page":"153","volume":"vol. 15","author":"Wani","year":"2021"},{"issue":"1","key":"10.1016\/j.mjafi.2025.03.003_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-18391-6","article-title":"Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial","volume":"12","author":"Hsiao","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.mjafi.2025.03.003_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/luts.12481","article-title":"Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms-A randomized controlled trial","volume":"15","author":"Chen","year":"2023","journal-title":"Low Urin Tract Symptoms"},{"issue":"1","key":"10.1016\/j.mjafi.2025.03.003_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23795-5","article-title":"Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study","volume":"12","author":"Tang","year":"2022","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.mjafi.2025.03.003_bib29","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jfma.2022.04.004","article-title":"Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders-A cohort study","volume":"121","author":"Chen","year":"2022","journal-title":"J Formos Med Assoc"},{"issue":"4","key":"10.1016\/j.mjafi.2025.03.003_bib30","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/luts.12384","article-title":"Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder","volume":"13","author":"Wang","year":"2021","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.mjafi.2025.03.003_bib31","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00345-020-03425-3","article-title":"Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO","volume":"39","author":"Soliman","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.mjafi.2025.03.003_bib32","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1097\/JU.0000000000001440","article-title":"Persistence and adherence of anticholinergics and beta-3 agonist for the treatment of overactive bladder: systematic review and meta-analysis, and network meta-analysis","volume":"205","author":"Song","year":"2021","journal-title":"J Urol"},{"issue":"11\u201312","key":"10.1016\/j.mjafi.2025.03.003_bib33","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1159\/000515992","article-title":"Mirabegron versus solifenacin in children with overactive bladder: prospective randomized single-blind controlled trial","volume":"105","author":"Soliman","year":"2021","journal-title":"Urol Int"},{"issue":"1","key":"10.1016\/j.mjafi.2025.03.003_bib34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/luts.12286","article-title":"Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: a post hoc analysis from the Japanese MILAI II study","volume":"12","author":"Katoh","year":"2020","journal-title":"Low Urin Tract Symptoms"},{"issue":"5","key":"10.1016\/j.mjafi.2025.03.003_bib35","first-page":"387","article-title":"Comparison of two different drugs for overactive bladder, solifenacin and mirabegron: a prospective randomized crossover study","volume":"73","author":"Inoue","year":"2019","journal-title":"Acta Med Okayama"},{"key":"10.1016\/j.mjafi.2025.03.003_bib36","first-page":"1603","volume":"vol. 30","author":"Hsu","year":"2019"},{"issue":"4","key":"10.1016\/j.mjafi.2025.03.003_bib37","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1590\/s1677-5538.ibju.2018.0518","article-title":"Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence","volume":"45","author":"Ozkidik","year":"2019","journal-title":"Int Braz J Urol"},{"issue":"3","key":"10.1016\/j.mjafi.2025.03.003_bib38","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/iju.13868","article-title":"Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: a multicenter, randomized study in Japan (MILAI II study)","volume":"26","author":"Yamaguchi","year":"2019","journal-title":"Int J Urol"},{"issue":"2","key":"10.1016\/j.mjafi.2025.03.003_bib39","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/nau.23919","article-title":"Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study","volume":"38","author":"Mueller","year":"2019","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"10.1016\/j.mjafi.2025.03.003_bib40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/luts.12167","article-title":"Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study","volume":"10","author":"Hsiao","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"issue":"3","key":"10.1016\/j.mjafi.2025.03.003_bib41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000361079","article-title":"The role of mirabegron in overactive bladder: a systematic review and meta-analysis","volume":"93","author":"Wu","year":"2014","journal-title":"Urol Int"},{"issue":"2","key":"10.1016\/j.mjafi.2025.03.003_bib42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00192-017-3377-5","article-title":"A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)","volume":"29","author":"Staskin","year":"2018","journal-title":"Int Urogynecol J"},{"issue":"2","key":"10.1016\/j.mjafi.2025.03.003_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40261-014-0240-z","article-title":"Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom","volume":"35","author":"Aball\u00e9a","year":"2015","journal-title":"Clin Drug Invest"},{"issue":"1","key":"10.1016\/j.mjafi.2025.03.003_bib44","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-018-0892-0","article-title":"Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)","volume":"16","author":"Herschorn","year":"2018","journal-title":"Health Qual Life Outcome"},{"issue":"9","key":"10.1016\/j.mjafi.2025.03.003_bib45","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/iju.14608","article-title":"Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: a multicenter randomized trial","volume":"28","author":"Suzuki","year":"2021","journal-title":"Int J Urol"},{"issue":"8","key":"10.1016\/j.mjafi.2025.03.003_bib46","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/14737167.2022.2130761","article-title":"Cost-effectiveness evaluation of mirabegron versus anti-muscarinics and third-line therapies: a systematic review","volume":"22","author":"Mohammadnezhad","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.mjafi.2025.03.003_bib47","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/nau.23935","article-title":"Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: a randomized, prospective trial using urodynamic studies","volume":"38","author":"Matsukawa","year":"2019","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"10.1016\/j.mjafi.2025.03.003_bib48","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/nau.24793","article-title":"Neurological safety and efficacy of darifenacin and mirabegron for the treatment of overactive bladder in patients with history of cerebrovascular accident: a prospective study","volume":"40","author":"Vasudeva","year":"2021","journal-title":"Neurourol Urodyn"}],"container-title":["Medical Journal Armed Forces India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0377123725000541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0377123725000541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T22:53:36Z","timestamp":1769036016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0377123725000541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0377123725000541"],"URL":"https:\/\/doi.org\/10.1016\/j.mjafi.2025.03.003","relation":{},"ISSN":["0377-1237"],"issn-type":[{"value":"0377-1237","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the therapeutic potential of beta-3 adrenergic agonists in overactive bladder: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Medical Journal Armed Forces India","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mjafi.2025.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}